PURPOSE: Lack of trust and rapport with health care providers has been identified in the under-representation of racial/ethnic minorities within clinical trials. Our study used a coach to promote trust among minority patients with advanced cancer. PATIENTS AND METHODS: Minority patients with advanced breast, colorectal, lung, or prostate carcinoma were randomly assigned to receive a coach Intervention (CI) or usual care (UC). All patients completed baseline and 6-month telephone interviews to assess demographics, trust in health care providers, attitudes toward clinical trials, and quality of life. Patients randomly assigned to CI were assigned a coach, who made biweekly contacts for 6 months to address general issues, progress or development in cancer care, and available resources. Patients randomly assigned to UC received the standard of care, without this intervention. Clinical trial enrollment was assessed. RESULTS: Over 21 months, we screened 268 patients and enrolled 73 African Americans and two Asian Americans. Patients were randomly assigned to CI (n = 38) or to UC (n = 37). Longitudinal analyses were conducted on 69 patients who completed the 6-month follow-up assessment. Trial enrollment was 16 and 13 patients for the CI and UC groups, respectively. This difference was not significant (P = .351). Higher quality of life (1-point odds ratio on Functional Assessment of Cancer Treatment-General = 1.033, P = .036) and positive attitudes toward trials predicted enrollment. There was no significant difference between these groups in quality of life, attitudes toward clinical trials, perceptions of racism, trust in doctors, or depression. CONCLUSIONS:Quality of life and positive attitude toward trials predicted trial enrollment, regardless of assignment to CI or UC.
RCT Entities:
PURPOSE: Lack of trust and rapport with health care providers has been identified in the under-representation of racial/ethnic minorities within clinical trials. Our study used a coach to promote trust among minority patients with advanced cancer. PATIENTS AND METHODS: Minority patients with advanced breast, colorectal, lung, or prostate carcinoma were randomly assigned to receive a coach Intervention (CI) or usual care (UC). All patients completed baseline and 6-month telephone interviews to assess demographics, trust in health care providers, attitudes toward clinical trials, and quality of life. Patients randomly assigned to CI were assigned a coach, who made biweekly contacts for 6 months to address general issues, progress or development in cancer care, and available resources. Patients randomly assigned to UC received the standard of care, without this intervention. Clinical trial enrollment was assessed. RESULTS: Over 21 months, we screened 268 patients and enrolled 73 African Americans and two Asian Americans. Patients were randomly assigned to CI (n = 38) or to UC (n = 37). Longitudinal analyses were conducted on 69 patients who completed the 6-month follow-up assessment. Trial enrollment was 16 and 13 patients for the CI and UC groups, respectively. This difference was not significant (P = .351). Higher quality of life (1-point odds ratio on Functional Assessment of Cancer Treatment-General = 1.033, P = .036) and positive attitudes toward trials predicted enrollment. There was no significant difference between these groups in quality of life, attitudes toward clinical trials, perceptions of racism, trust in doctors, or depression. CONCLUSIONS: Quality of life and positive attitude toward trials predicted trial enrollment, regardless of assignment to CI or UC.
Authors: Ralph V Katz; S Steven Kegeles; Nancy R Kressin; B Lee Green; Min Qi Wang; Sherman A James; Stefanie Luise Russell; Cristina Claudio Journal: J Health Care Poor Underserved Date: 2006-11
Authors: Donna Kalauokalani; Peter Franks; Jennifer Wright Oliver; Frederick J Meyers; Richard L Kravitz Journal: Pain Med Date: 2007 Jan-Feb Impact factor: 3.750
Authors: Warren B Sateren; Edward L Trimble; Jeffrey Abrams; Otis Brawley; Nancy Breen; Leslie Ford; Mary McCabe; Richard Kaplan; Malcolm Smith; Richard Ungerleider; Michaele C Christian Journal: J Clin Oncol Date: 2002-04-15 Impact factor: 44.544
Authors: Zarnie Lwin; Alexander Broom; Rasha Cosman; Ann Livingstone; Kate Sawkins; Phillip Good; Emma Kirby; Eng-Siew Koh; Elizabeth Hovey Journal: Neurooncol Pract Date: 2014-06-25
Authors: Ersilia M DeFilippis; Melvin Echols; Philip B Adamson; Wayne B Batchelor; Lauren B Cooper; Lawton S Cooper; Patrice Desvigne-Nickens; Richard T George; Nasrien E Ibrahim; Mariell Jessup; Dalane W Kitzman; Eric S Leifer; Martin Mendoza; Ileana L Piña; Mitchell Psotka; Fortunato Fred Senatore; Kenneth M Stein; John R Teerlink; Clyde W Yancy; JoAnn Lindenfeld; Mona Fiuzat; Christopher M O'Connor; Orly Vardeny; Muthiah Vaduganathan Journal: JAMA Cardiol Date: 2022-05-01 Impact factor: 30.154
Authors: Barbara C Tilley; Arch G Mainous; Rossybelle P Amorrortu; M Diane McKee; Daniel W Smith; Ruosha Li; Stacia M DeSantis; Sally W Vernon; Gary Koch; Marvella E Ford; Vanessa Diaz; Jennifer Alvidrez Journal: Contemp Clin Trials Date: 2021-07-30 Impact factor: 2.261
Authors: Helena Walz; Barbara Bohn; Jessica Sander; Claudia Eberle; Monika Alisch; Bernhard Oswald; Anja Kroke Journal: AIMS Public Health Date: 2015-08-21